General Information of Drug Transporter (DT)
DT ID	DTD0004 Transporter Info
Gene Name	ABCG2
Protein Name	Breast cancer resistance protein
Gene ID	9429
UniProt ID	Q9UNQ0
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs1061018
Site of GPD	chr4:88121701 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Allele G	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity of drug in K562 cells (compare with Allele A)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity of drug in K562 cells (compare with Allele A)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity of drug in K562 cells (compare with Allele A)		[ 1]
Dasatinib	N.A.	Adverse Events	Allele G is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele A.		[ 1]
Imatinib	N.A.	Adverse Events	Allele G is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele A.		[ 1]
Nilotinib	N.A.	Adverse Events	Allele G is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele A.		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AG genotype are not studied. But based on in-vitro experiments the G allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AG genotype are not studied. But based on in-vitro experiments the G allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AG genotype are not studied. But based on in-vitro experiments the G allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Genetic Polymorphism	rs13120400
Site of GPD	chr4:88112375 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.1052/527 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Methotrexate	Drug Info	Psoriasis	Correlated with the increased drug response in patients (compare with genotypes tt + Ct)		[ 2]
Voriconazole	N.A.	Drug Toxicity	Genotype CC is associated with increased trough concentration of voriconazole in children as compared to genotypes CT + TT.		[ 3]
Methotrexate	N.A.	Drug Toxicity	Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CT + TT.		[ 2]
Deferasirox	N.A.	Death	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.		[ 4]
Methotrexate	N.A.	Neutropenia	Genotype CC is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes CT + TT.		[ 5]
Methotrexate	N.A.	Osteosarcoma	Genotype CC is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes CT + TT.		[ 5]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Methotrexate	N.A.	Psoriasis	Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CT + TT.		[ 2]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.		[ 4]
Ceftriaxone	N.A.	Central Nervous System Infectious Disorder	Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.		[ 7]
Exjade	N.A.	Beta-Thalassemia	Correlated with the increased drug concentrations in patients (compare with Genotypes CT + TT)		[ 4], [ 8]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased drug response in patients (compare with Genotype TT)		[ 6]
Imatinib	N.A.	Drug Toxicity	Genotypes CC + CT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.		[ 6]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotypes CC + CT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.		[ 6]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Genotypes CT + TT is associated with increased severity of Drug Toxicity when treated with methotrexate in people with Psoriasis as compared to genotype CC.		[ 9]
Deferasirox	N.A.	Drug-induced Liver Injury	Genotypes CT + TT is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype CC.		[ 10]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Genotypes CT + TT is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype CC.		[ 10]
Exjade	N.A.	Beta-Thalassemia	Correlated with the increased drug exposure in patients (compare with genotype CC)		[ 10]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Ceftriaxone	N.A.	Neutropenia	Genotype TT is associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes CC + CT.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.		[ 5]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Methotrexate	N.A.	Psoriasis	Patients with the TT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 2]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Patients with the TT genotype and beta-thalassemia who are treated with deferasirox may have an worse response to deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.		[ 4]
Ceftriaxone	N.A.	Central Nervous System Infectious Disorder	Genotype TT is associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes CC + CT.		[ 7]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the CT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.		[ 5]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Methotrexate	N.A.	Psoriasis	Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 2]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Patients with the CT genotype and beta-thalassemia who are treated with deferasirox may have decreased concentrations of deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.		[ 4]
Ceftriaxone	N.A.	Central Nervous System Infectious Disorder	Patients with central nervous system infections and the CT genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.		[ 7]
Genetic Polymorphism	rs2231135
Site of GPD	chr4:88158842 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.0333/167 (Global)
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased mucositis risk in patients (compare with genotype AA)		[ 11]
Methotrexate	N.A.	Mucositis	Genotype AG is associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma as compared to genotype AA.		[ 11]
Methotrexate	N.A.	Osteosarcoma	Genotype AG is associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma as compared to genotype AA.		[ 11]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Osteosarcoma	Patients with the AA genotype and osteosarcoma may be at decreased risk for mucositis when receiving methotrexate, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.		[ 11]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Osteosarcoma	No patients with the GG genotype were available for analysis, but patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.		[ 11]
Genetic Polymorphism	rs2231137
Site of GPD	chr4:88139962 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1575/789 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Dasatinib	N.A.	Adverse Events	Allele T is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele C.		[ 1]
Imatinib	N.A.	Adverse Events	Allele T is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele C.		[ 1]
Nilotinib	N.A.	Adverse Events	Allele T is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele C.		[ 1]
Pravastatin	N.A.	Drug-induced Liver Injury	Allele T is not associated with pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to allele C.		[ 13]
Sunitinib	N.A.	Drug Toxicity	Allele T is associated with increased concentrations of sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to allele C.		[ 14]
Imatinib	N.A.	Drug Toxicity	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 15]
Imatinib	N.A.	Discontinuation	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 15]
Antiepileptics	N.A.	Discontinuation	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.		[ 16]
Sunitinib	N.A.	Drug Toxicity	Allele T is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele C.		[ 17]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:         10 Drugs in Total
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased diarrhea risk in patients (compare with genotype CC); Irrelevant to the neutropenia in patients (compare with genotype CC)		[ 17]
Irinotecan	N.A.	Diarrhea	Genotypes CT + TT are associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.		[ 17]
Valganciclovir	N.A.	Neutropenia	Genotypes CT + TT is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.		[ 18]
Osimertinib	N.A.	Event-free Survival	Genotypes CT + TT is associated with decreased event-free survival when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.		[ 19]
Irinotecan	N.A.	Neutropenia	Genotypes CT + TT are not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.		[ 17]
Imatinib	N.A.	Death	Genotypes CT + TT are associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 14]
Methotrexate	N.A.	Mucositis	Genotypes CT + TT are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 21]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Genotypes CT + TT are associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.		[ 17]
Imatinib	N.A.	Drug Toxicity	Genotypes CT + TT are associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 14]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotypes CT + TT are associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 14]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         10 Drugs in Total
Palbociclib	N.A.	Neutropenia	Genotype CT is associated with increased likelihood of Neutropenia when treated with palbociclib in people with Breast Neoplasms as compared to genotype CC.		[ 21]
Sunitinib	N.A.	Progression-free Survival	Genotype CT is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.		[ 22]
Sorafenib	N.A.	Neutropenia	Genotype CT is associated with concentrations of sorafenib in people with Carcinoma, Hepatocellular as compared to genotype CC.		[ 23]
Pazopanib	N.A.	Discontinuation	Genotype CT is not associated with decreased clearance of pazopanib in people with Neoplasms as compared to genotype CC.		[ 24]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Patients with the CT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.		[ 17]
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Drug Toxicity	Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.		[ 14]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.		[ 14]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele C is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 25]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 20]
Talinolol	N.A.	Event-free Survival	Allele C is not associated with clearance of talinolol in healthy individuals as compared to allele T.		[ 27]
Lamotrigine	N.A.	Exanthema	Allele C is not associated with response to lamotrigine in people with Epilepsy as compared to allele T.		[ 28]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Genotypes CC + CT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 20]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Methotrexate	N.A.	Mucositis	Genotype CC is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CT.		[ 28]
Antineoplastic Agents	N.A.	Toxic Liver Disease	Genotype CC is not associated with response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 29]
Chop	N.A.	Progression-free Survival	Genotype CC is associated with decreased progression-free survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotypes CT + TT.		[ 30]
Rituximab	N.A.	Progression-free Survival	Genotype CC is associated with decreased progression-free survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotypes CT + TT.		[ 30]
Lamotrigine	N.A.	Exanthema	Genotype CC is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.		[ 27]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Patients with the CC genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.		[ 17]
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Drug Toxicity	Patients with the CC genotype may be less likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.		[ 14]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CC genotype may be less likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.		[ 14]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Granisetron	N.A.	Nephrotoxicity	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CT.		[ 31]
Palonosetron	N.A.	Nephrotoxicity	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CT.		[ 31]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Patients with the TT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.		[ 17]
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Drug Toxicity	Patients with the TT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.		[ 14]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the TT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.		[ 14]
Genetic Polymorphism	rs2231142
Site of GPD	chr4:88131171 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C / G>T
Minor Allele Frequency	T=0.1194/598 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:         26 Drugs in Total
Lamotrigine	Drug Info	Epilepsy	Irrelevant to the drug concentrations in patients (compare with Allele T); Irrelevant to the drug response in patients (compare with Allele T)		[ 27], [ 32]
Methotrexate	Drug Info	Rheumatoid Arthritis	Irrelevant to the drug discontinuation in patients (compare with Allele T)		[ 28]
Gemcitabine	Drug Info	Non-Small-Cell Lung Carcinoma	Irrelevant to the severity of neutropenia in patients (compare with Allele T)		[ 35]
Lamotrigine	N.A.	Drug Toxicity	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.		[ 32]
Hmg Coa Reductase Inhibitors	N.A.	Toxic Liver Disease	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.		[ 36]
Methotrexate	N.A.	Mucositis	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 28]
Methotrexate	N.A.	Nephrotoxicity	Allele G is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.		[ 37]
Methotrexate	N.A.	Nephrotoxicity	Allele G is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 37]
Talinolol	N.A.	Event-free Survival	Allele G is not associated with clearance of talinolol in healthy individuals as compared to allele T.		[ 26]
Tacrolimus	N.A.	Neutropenia	Allele G is not associated with adverse events when treated with tacrolimus in children with hematopoietic stem cell transplant as compared to allele T.		[ 39]
Imatinib	N.A.	Death	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.		[ 14]
Apixaban	N.A.	Neutropenia	Allele G is associated with decreased concentrations of apixaban in people with Atrial Fibrillation as compared to allele T.		[ 41]
Gemcitabine	N.A.	Neutropenia	Allele G is not associated with severity of Neutropenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.		[ 35]
Imatinib	N.A.	Drug Toxicity	Allele G is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.		[ 14]
Imatinib	N.A.	Discontinuation	Allele G is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.		[ 14]
Lamotrigine	N.A.	Exanthema	Allele G is not associated with response to lamotrigine in people with Epilepsy as compared to allele T.		[ 27]
Apixaban	N.A.	Hemorrhage	Allele G is not associated with increased likelihood of Hemorrhage or Thromboembolism when treated with apixaban in people with Atrial Fibrillation as compared to allele T.		[ 41]
Apixaban	N.A.	Thromboembolism	Allele G is not associated with increased likelihood of Hemorrhage or Thromboembolism when treated with apixaban in people with Atrial Fibrillation as compared to allele T.		[ 41]
Leflunomide	N.A.	Hemorrhage	Allele G is not associated with increased clinical benefit to leflunomide in people with Arthritis, Rheumatoid as compared to allele T.		[ 42]
Lamotrigine	N.A.	Epilepsy	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.		[ 32]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 28]
Gemcitabine	N.A.	Non-small Cell Lung Carcinoma	Allele G is not associated with severity of Neutropenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.		[ 35]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 37]
Methotrexate	N.A.	Burkitt Lymphoma	Allele G is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 37]
Methotrexate	N.A.	Lymphoma, T-cell	Allele G is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 37]
Methotrexate	N.A.	Osteosarcoma	Allele G is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 37]
Allele T	Click to Show/Hide the Full List of Affected Drugs:         77 Drugs in Total
Allopurinol	Drug Info	Gout	Correlated with the decreased drug response in patients (compare with allele G); Correlated with the increased drug dose in patients (compare with allele G)		[ 39], [ 40]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased LDL-C in patients (compare with allele G); Correlated with the increased drug plasma concentrations in patients (compare with allele G); Correlated with the increased drug response in patients (compare with allele G); Correlated with the increased reduction in low-density lipoprotein cholesterol (LDL-C) level in patients (compare with allele G)		[ 41], [ 42], [ 43], [ 44]
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with allele G)		[ 32]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with allele G)		[ 46]
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele G)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele G)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with allele G)		[ 1]
Gefitinib	Drug Info	Lung Neoplasm	Irrelevant to the increased drug toxicity risk in patients (compare with allele G)		[ 48]
Rosuvastatin	N.A.	Adverse Events	Allele T is associated with increased reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner, when treated with rosuvastatin in people with Hypercholesterolemia as compared to allele G.		[ 44]
Imatinib	N.A.	Neutropenia	Allele T is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.		[ 49]
Dasatinib	N.A.	Neutropenia	Allele T is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele G.		[ 1]
Imatinib	N.A.	Neutropenia	Allele T is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele G.		[ 1]
Nilotinib	N.A.	Neutropenia	Allele T is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele G.		[ 1]
Imatinib	N.A.	Exanthema	Allele T is associated with increased severity of Exanthema when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 50]
Axitinib	N.A.	Progression-free Survival	Allele T is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 51]
Pitavastatin	N.A.	Adverse Events	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.		[ 52]
Allopurinol	N.A.	Drug Toxicity	Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.		[ 53]
Rosuvastatin	N.A.	Hypercholesterolemia	Allele T is associated with severity of Hypercholesterolemia when treated with rosuvastatin as compared to allele G.		[ 42]
Lamotrigine	N.A.	Discontinuation	Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G.		[ 32]
Allopurinol	N.A.	Toxic Liver Disease	Allele T is associated with increased dose of allopurinol in people with Gout as compared to allele G.		[ 40]
Letermovir	N.A.	Mucositis	Allele T is not associated with exposure to letermovir as compared to allele G.		[ 54]
Methotrexate	N.A.	Mucositis	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 55]
Selumetinib	N.A.	Nephrotoxicity	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele G.		[ 56]
Pravastatin	N.A.	Drug-induced Liver Injury	Allele T is not associated with pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to allele G.		[ 12]
Gefitinib	N.A.	Neutropenia	Allele T is not associated with decreased response to gefitinib in people with Non-Small Cell Lung Carcinoma as compared to allele G.		[ 58]
Methotrexate	N.A.	Toxic Liver Disease	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 59]
Rosuvastatin	N.A.	Drug Toxicity	Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.		[ 43]
Sulfasalazine	N.A.	Toxic Liver Disease	Allele T is not associated with discontinuation of sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.		[ 60]
Allopurinol	N.A.	Toxic Liver Disease	Allele T is associated with decreased response to allopurinol as compared to allele G.		[ 61]
Sunitinib	N.A.	Thrombocytopenia	Allele T is associated with increased severity of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 62]
Ceftriaxone	N.A.	Neutropenia	Allele T is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.		[ 7]
Rivaroxaban	N.A.	Neutropenia	Allele T is not associated with decreased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele G.		[ 64]
Gefitinib	N.A.	Drug Toxicity	Allele T is not associated with increased risk of Drug Toxicity when treated with gefitinib as compared to allele G.		[ 48]
Imatinib	N.A.	Drug Toxicity	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.		[ 65]
Pitavastatin	N.A.	Neutropenia	Allele T is not associated with increased concentrations of pitavastatin in healthy individuals as compared to allele G.		[ 66]
Rosuvastatin	N.A.	Discontinuation	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.		[ 46]
Antiepileptics	N.A.	Discontinuation	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 15]
Methotrexate	N.A.	Mucositis	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.		[ 68]
Lamotrigine	N.A.	Thromboembolism	Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele G.		[ 69]
Rosuvastatin	N.A.	Thromboembolism	Allele T is associated with increased plasma concentrations of rosuvastatin as compared to allele G.		[ 41]
Methotrexate	N.A.	Drug Toxicity	Allele T is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 70]
Sunitinib	N.A.	Drug Toxicity	Allele T is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 16]
Methotrexate	N.A.	Drug Toxicity	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 72]
Diflomotecan	N.A.	Drug Toxicity	Allele T is associated with increased plasma concentrations of diflomotecan when treated with diflomotecan as compared to allele G.		[ 73]
Sunitinib	N.A.	Neoplasms	Allele T is associated with increased severity of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 62]
Lamotrigine	N.A.	Epilepsy	Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele G.		[ 69]
Lamotrigine	N.A.	Epilepsy	Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G.		[ 32]
Gefitinib	N.A.	Lung Neoplasms	Allele T is not associated with increased risk of Drug Toxicity when treated with gefitinib as compared to allele G.		[ 48]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 72]
Methotrexate	N.A.	Burkitt Lymphoma	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 72]
Methotrexate	N.A.	Lymphoma, T-cell	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 72]
Methotrexate	N.A.	Osteosarcoma	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 72]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 59]
Methotrexate	N.A.	Burkitt Lymphoma	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 59]
Methotrexate	N.A.	Lymphoma, T-cell	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 59]
Methotrexate	N.A.	Osteosarcoma	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 59]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.		[ 68]
Methotrexate	N.A.	Burkitt Lymphoma	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.		[ 68]
Methotrexate	N.A.	Lymphoma, T-cell	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.		[ 68]
Methotrexate	N.A.	Osteosarcoma	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.		[ 68]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 70]
Methotrexate	N.A.	Burkitt Lymphoma	Allele T is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 70]
Methotrexate	N.A.	Lymphoma, T-cell	Allele T is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 70]
Methotrexate	N.A.	Osteosarcoma	Allele T is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 70]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 55]
Methotrexate	N.A.	Burkitt Lymphoma	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 55]
Methotrexate	N.A.	Drug Toxicity	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 55]
Methotrexate	N.A.	Lymphoma, T-cell	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 55]
Methotrexate	N.A.	Osteosarcoma	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 55]
Rosuvastatin	N.A.	Hypercholesterolemia	Allele T is associated with increased reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner, when treated with rosuvastatin in people with Hypercholesterolemia as compared to allele G.		[ 44]
Rosuvastatin	N.A.	Myocardial Infarction	Allele T is associated with increased reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner, when treated with rosuvastatin in people with Hypercholesterolemia as compared to allele G.		[ 44]
Rosuvastatin	N.A.	Myocardial Infarction	Allele T is associated with severity of Hypercholesterolemia when treated with rosuvastatin as compared to allele G.		[ 42]
Rosuvastatin	N.A.	Hypercholesterolemia	Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.		[ 43]
Rosuvastatin	N.A.	Myocardial Infarction	Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.		[ 43]
Allopurinol	N.A.	Gout	Allele T is associated with increased dose of allopurinol in people with Gout as compared to allele G.		[ 40]
Allopurinol	N.A.	Gout	Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.		[ 53]
Allopurinol	N.A.	Gout	Allele T is associated with decreased response to allopurinol as compared to allele G.		[ 61]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:         82 Drugs in Total
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the decreased drug response in patients (compare with Genotypes GT + TT)		[ 29]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the decreased drug response in patients (compare with Genotypes GT + TT); Irrelevant to the drug response in patients (compare with Genotypes GT + TT)		[ 29], [ 69]
Oxaliplatin	Drug Info	Colorectal Neoplasm	Correlated with the decreased drug response in patients (compare with Genotypes GT + TT); Irrelevant to the drug response in patients (compare with Genotypes GT + TT)		[ 29], [ 69]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased percentage change in LDL-cholesterol levels in patients (compare with Genotype TT)		[ 70]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the decreased the total area under the plasma concentration-time curve (AUC) of drug in healthy individuals (compare with genotypes tt + Gt)		[ 71]
Irinotecan	Drug Info	Colorectal Neoplasm	Irrelevant to the drug response in patients (compare with Genotypes GT + TT)		[ 69]
Gefitinib	Drug Info	Non-Small-Cell Lung Carcinoma	Irrelevant to the drug toxicity risk in patients (compare with Genotypes GT + TT); Irrelevant to the increased likelihood of drug toxicity in patients (compare with Genotypes GT + TT)		[ 72], [ 73]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the decreased drug response in patients (compare with Genotypes GT + TT)		[ 29]
Gefitinib	N.A.	Diarrhea	Genotype GG is associated with increased likelihood of Diarrhea when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 74]
Rosuvastatin	N.A.	Diarrhea	Genotype GG is associated with decreased AUC of rosuvastatin in people with no disease as compared to genotypes GT + TT.		[ 71]
Dolutegravir	N.A.	Discontinuation	Genotype GG is not associated with likelihood of Discontinuation and adverse events when treated with dolutegravir in people with HIV infectious disease as compared to genotype GT.		[ 75]
Dolutegravir	N.A.	Adverse Events	Genotype GG is not associated with likelihood of Discontinuation and adverse events when treated with dolutegravir in people with HIV infectious disease as compared to genotype GT.		[ 75]
Lenvatinib	N.A.	Dry Mouth	Genotype GG is associated with increased severity of dry mouth and mucositis when treated with lenvatinib in people with Thyroid Neoplasms as compared to genotype GT.		[ 76]
Lenvatinib	N.A.	Mucositis	Genotype GG is associated with increased severity of dry mouth and mucositis when treated with lenvatinib in people with Thyroid Neoplasms as compared to genotype GT.		[ 76]
Osimertinib	N.A.	Diarrhea	Genotype GG is associated with increased likelihood of Diarrhea when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 77]
Fluorouracil	N.A.	Adverse Events	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Irinotecan	N.A.	Adverse Events	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Oxaliplatin	N.A.	Adverse Events	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Gefitinib	N.A.	Drug Toxicity	Genotype GG is not associated with increased likelihood of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 73]
Gefitinib	N.A.	Drug Toxicity	Genotype GG is not associated with increased overall survival when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 73]
Fluorouracil	N.A.	Drug Toxicity	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Irinotecan	N.A.	Drug Toxicity	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Oxaliplatin	N.A.	Drug Toxicity	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Rosuvastatin	N.A.	Drug Toxicity	Genotype GG is associated with decreased percentage change in LDL-cholesterol levels when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 70]
Irinotecan	N.A.	Neutropenia	Genotype GG is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 17]
Irinotecan	N.A.	Diarrhea	Genotype GG is not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 17]
Antineoplastic Agents	N.A.	Toxic Liver Disease	Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 29]
Gefitinib	N.A.	Neutropenia	Genotype GG are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 72]
Gefitinib	N.A.	Neutropenia	Genotype GG is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 79]
Deferasirox	N.A.	Discontinuation	Genotype GG is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes GT + TT.		[ 8]
Dexmedetomidine	N.A.	Sedation	Genotype GG is associated with increased severity of sedation when treated with dexmedetomidine in people with surgery as compared to genotypes GT + TT.		[ 81]
Hmg Coa Reductase Inhibitors	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotype GG is not associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotype GT.		[ 82]
Gefitinib	N.A.	Drug Toxicity	Genotype GG is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 72]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the GG genotype and HIV may have decreased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence AUC of tenofovir.		[ 83]
Capecitabine	N.A.	Colorectal Neoplasms	Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 29]
Fluorouracil	N.A.	Colorectal Neoplasms	Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 29]
Leucovorin	N.A.	Colorectal Neoplasms	Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 29]
Oxaliplatin	N.A.	Colorectal Neoplasms	Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 29]
Capecitabine	N.A.	Colorectal Neoplasms	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Fluorouracil	N.A.	Colorectal Neoplasms	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Leucovorin	N.A.	Colorectal Neoplasms	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Oxaliplatin	N.A.	Colorectal Neoplasms	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.		[ 69]
Sulfasalazine	N.A.	Rheumatoid Arthritis	Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.		[ 57]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the GG genotype and HIV infection who are treated with efavirenz may have a reduced risk of abnormal dreams as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.		[ 85]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 86]
Sunitinib	N.A.	Neoplasms	Patients with the GG genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.		[ 87]
Lamotrigine	N.A.	Epilepsy	Patients with the rs2231142 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the GT and TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.		[ 64]
Atorvastatin	N.A.	Epilepsy	Patients with the GG genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.		[ 89]
Fluvastatin	N.A.	Epilepsy	Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.		[ 90]
Simvastatin	N.A.	Epilepsy	Patients with the rs2231142 GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.		[ 90]
Atorvastatin	N.A.	Epilepsy	Patients with the rs2231142 GG genotype may have a decreased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.		[ 91]
Rosuvastatin	N.A.	Epilepsy	The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GG genotype may have decreased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.		[ 92]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the GG genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate toxicity.		[ 93]
Gefitinib	N.A.	Lung Neoplasms	Genotype GG is not associated with increased likelihood of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 73]
Gefitinib	N.A.	Lung Neoplasms	Genotype GG is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 72]
Gefitinib	N.A.	Lung Neoplasms	Patients with the GG genotype and lung cancer may have a decreased risk of diarrhea when treated with gefitinib as compared to patients with the GT genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.		[ 94]
Gemcitabine	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and non-small cell lung cancer may have shorter progression-free survival, and decreased severity of thrombocytopenia, as compared to patients with the GT and TT genotypes. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.		[ 33]
Dolutegravir	N.A.	HIV Infectious Disease	Patients with the GG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.		[ 96]
Sulfasalazine	N.A.	Beta-thalassemia And Related Diseases	Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.		[ 97]
Apixaban	N.A.	Atrial Fibrillation	Patients atrial fibrillation and the GG genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.		[ 98]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 99]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 99]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 99]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 100]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 100]
Methotrexate	N.A.	Lymphoma, T-cell	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 100]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 100]
Opioid Anesthetics	N.A.	Osteosarcoma	Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.		[ 101]
Other General Anesthetics	N.A.	Osteosarcoma	Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.		[ 101]
Volatile Anesthetics	N.A.	Osteosarcoma	Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.		[ 101]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 102]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 102]
Methotrexate	N.A.	Drug Toxicity	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 102]
Methotrexate	N.A.	Lymphoma, T-cell	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 102]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 102]
Rosuvastatin	N.A.	Statin-related Myopathy	The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GG genotype may have a lower risk of statin-related myopathy when treated with rosuvastatin as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.		[ 92]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotype GG is associated with decreased percentage change in LDL-cholesterol levels when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 70]
Rosuvastatin	N.A.	Myocardial Infarction	Genotype GG is associated with decreased percentage change in LDL-cholesterol levels when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 70]
Rosuvastatin	N.A.	Hypercholesterolemia	Patients with the rs2231142 GG genotype and who are treated with rosuvastatin may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 44]
Rosuvastatin	N.A.	Myocardial Infarction	Patients with the rs2231142 GG genotype and who are treated with rosuvastatin may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 44]
Allopurinol	N.A.	Gout	Patients with the rs2231142 GG genotype may require a decreased dose of allopurinol as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence allopurinol dose requirements.		[ 40]
Allopurinol	N.A.	Gout	Patients with the rs2231142 GG genotype and gout may have increased response when treated with allopurinol as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence allopurinol response.		[ 51]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:         66 Drugs in Total
Imatinib	Drug Info	Neoplasm	Correlated with the decreased drug metabolism in patients (compare with genotype GG)		[ 82]
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotype GG)		[ 93]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotype GG)		[ 93]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotype GG)		[ 93]
Sulfasalazine	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotype GG)		[ 91]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotype GG)		[ 91]
Gefitinib	Drug Info	Lung Neoplasm	Correlated with the increased likelihood of diarrhea in patients (compare with genotype GG)		[ 89]
Rivaroxaban	N.A.	Adverse Events	Genotype GT is associated with increased likelihood of adverse events when treated with rivaroxaban in healthy individuals as compared to genotype GG.		[ 101]
Simvastatin	N.A.	Drug-induced Liver Injury	Genotype GT is associated with increased likelihood of drug-induced liver injury when treated with simvastatin in people with Coronary Artery Disease as compared to genotype TT.		[ 102]
Imatinib	N.A.	Adverse Events	Genotype GT is associated with decreased metabolism of imatinib in people with Neoplasms as compared to genotype GG.		[ 82]
Methotrexate	N.A.	Drug Toxicity	Genotype GT is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 96]
Rosuvastatin	N.A.	Drug Toxicity	Genotype GT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.		[ 91]
Sulfasalazine	N.A.	Drug Toxicity	Genotype GT is associated with increased exposure to sulfasalazine in healthy individuals as compared to genotype GG.		[ 91]
Acetaminophen	N.A.	Drug Toxicity	Genotype GT is not associated with clearance of acetaminophen as compared to genotype GG.		[ 104]
Levofloxacin	N.A.	Drug Toxicity	Genotype GT is associated with increased risk of seizures due to levofloxacin.		[ 105]
Gefitinib	N.A.	Drug Toxicity	Genotype GT is associated with increased likelihood of Diarrhea when treated with gefitinib in people with Lung Neoplasms as compared to genotype GG.		[ 89]
Sorafenib	N.A.	Neutropenia	Genotype GT is associated with concentrations of sorafenib in people with Carcinoma, Hepatocellular as compared to genotype GG.		[ 23]
Leflunomide	N.A.	Discontinuation	Genotype GT is not associated with decreased likelihood of discontinuation when treated with leflunomide in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 107]
Methotrexate	N.A.	Discontinuation	Genotype GT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 65]
Imatinib	N.A.	Discontinuation	Genotype GT is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.		[ 109]
Gefitinib	N.A.	Exanthema	Genotype GT is associated with increased severity of Exanthema when treated with gefitinib in women with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.		[ 110]
Cyclophosphamide	N.A.	Anemia	Genotype GT is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.		[ 93]
Doxorubicin	N.A.	Anemia	Genotype GT is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.		[ 93]
Fluorouracil	N.A.	Anemia	Genotype GT is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.		[ 93]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the GT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.		[ 80]
Capecitabine	N.A.	Colorectal Neoplasms	Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.		[ 29]
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.		[ 29]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.		[ 29]
Oxaliplatin	N.A.	Colorectal Neoplasms	Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.		[ 29]
Sulfasalazine	N.A.	Rheumatoid Arthritis	Patients with the GT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.		[ 57]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the GT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.		[ 81]
Sunitinib	N.A.	Neoplasms	Patients with the GT genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.		[ 83]
Lamotrigine	N.A.	Epilepsy	Patients with the rs2231142 GT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.		[ 64]
Atorvastatin	N.A.	Epilepsy	Patients with the GT genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.		[ 84]
Fluvastatin	N.A.	Epilepsy	Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.		[ 85]
Simvastatin	N.A.	Epilepsy	Patients with the rs2231142 GT genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.		[ 85]
Atorvastatin	N.A.	Epilepsy	Patients with the rs2231142 GT genotype may have an increased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.		[ 86]
Rosuvastatin	N.A.	Epilepsy	The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GT genotype may have increased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.		[ 87]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the GT genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype, or a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity.		[ 88]
Gefitinib	N.A.	Lung Neoplasms	Genotype GT is associated with increased likelihood of Diarrhea when treated with gefitinib in people with Lung Neoplasms as compared to genotype GG.		[ 89]
Gemcitabine	N.A.	Non-small Cell Lung Carcinoma	Patients with the GT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.		[ 33]
Dolutegravir	N.A.	HIV Infectious Disease	Patients with the TG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.		[ 90]
Apixaban	N.A.	Atrial Fibrillation	Patients atrial fibrillation and the GT genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.		[ 92]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotype GT is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.		[ 93]
Doxorubicin	N.A.	Breast Neoplasms	Genotype GT is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.		[ 93]
Fluorouracil	N.A.	Breast Neoplasms	Genotype GT is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.		[ 93]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype GT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 65]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype GT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 65]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype GT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 65]
Methotrexate	N.A.	Osteosarcoma	Genotype GT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 65]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 94]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 94]
Methotrexate	N.A.	Lymphoma, T-cell	The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 94]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 94]
Opioid Anesthetics	N.A.	Osteosarcoma	Patients with the GT genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.		[ 95]
Other General Anesthetics	N.A.	Osteosarcoma	Patients with the GT genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.		[ 95]
Volatile Anesthetics	N.A.	Osteosarcoma	Patients with the GT genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.		[ 95]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype GT is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 96]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype GT is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 96]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype GT is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 96]
Methotrexate	N.A.	Osteosarcoma	Genotype GT is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 96]
Rosuvastatin	N.A.	Statin-related Myopathy	The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GT genotype may have a higher risk of statin-related myopathy when treated with rosuvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.		[ 87]
Rosuvastatin	N.A.	Hypercholesterolemia	Patients with the rs2231142 GT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 44]
Rosuvastatin	N.A.	Myocardial Infarction	Patients with the rs2231142 GT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 44]
Allopurinol	N.A.	Gout	Patients with the rs2231142 GT genotype may require an increased dose of allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol dose requirements.		[ 40]
Allopurinol	N.A.	Gout	Patients with the rs2231142 GT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.		[ 51]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         86 Drugs in Total
Sulfasalazine	Drug Info	Healthy Individuals	Correlated with the decreased drug clearance in healthy individuals (compare with genotypes GG + Gt)		[ 104], [ 105]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased likelihood of adverse events in patients (compare with genotype GG)		[ 88]
Sunitinib	Drug Info	Renal Cell Carcinoma	Correlated with the decreased neutropenia risk in patients (compare with genotypes GG + Gt); Correlated with the increased drug toxicity risk in patients (compare with genotypes GG + Gt); Correlated with the increased hand-foot syndrome risk in patients (compare with genotypes GG + Gt); Correlated with the increased neutropenia risk in patients (compare with genotypes GG + Gt); Correlated with the increased thrombocytopenia risk in patients (compare with genotypes GG + Gt); Irrelevant to the anemia risk in patients (compare with genotypes GG + Gt)		[ 83], [ 108]
Apixaban	Drug Info	Atrial Fibrillation	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 92]
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with genotypes GG + Gt)		[ 27]
Dolutegravir	Drug Info	HIV Infection	Correlated with the increased drug concentrations in patients (compare with genotypes GG + Gt)		[ 90]
Fluvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotypes GG + Gt)		[ 85]
Simvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotypes GG + Gt)		[ 85]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug plasma concentrations in patients (compare with genotype GG)		[ 69]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased the total area under the plasma concentration-time curve (AUC) in healthy individuals (compare with genotypes GG + Gt)		[ 84]
Atorvastatin	Drug Info	Healthy Individuals	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in healthy individuals (compare with genotypes GG + Gt)		[ 84]
Pravastatin	N.A.	Neutropenia	Genotype TT is not associated with increased exposure to drug when treated with pravastatin in healthy individuals as compared to genotypes GG + GT.		[ 85]
Simvastatin	N.A.	Neutropenia	Genotype TT is associated with increased exposure to drug when treated with simvastatin in healthy individuals as compared to genotypes GG + GT.		[ 85]
Fluvastatin	N.A.	Neutropenia	Genotype TT is associated with increased exposure to drug when treated with fluvastatin in healthy individuals as compared to genotypes GG + GT.		[ 85]
Atorvastatin	N.A.	Diarrhea	Genotype TT is associated with increased AUC of atorvastatin in people with no disease as compared to genotypes GG + GT.		[ 84]
Rosuvastatin	N.A.	Diarrhea	Genotype TT is associated with increased AUC of rosuvastatin in people with no disease as compared to genotypes GG + GT.		[ 84]
Sulfasalazine	N.A.	Adverse Events	Genotype TT is associated with decreased clearance of sulfasalazine in healthy individuals as compared to genotypes GG + GT.		[ 105]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 115]
Sunitinib	N.A.	Drug Toxicity	Genotype TT is associated with increased risk of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 83]
Sunitinib	N.A.	Anemia	Genotype TT is not associated with risk of Anemia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 83]
Sunitinib	N.A.	Thrombocytopenia	Genotype TT is associated with increased risk of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 83]
Sunitinib	N.A.	Neutropenia	Genotype TT is associated with increased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 83]
Sunitinib	N.A.	Hand-foot Syndrome	Genotype TT is associated with increased risk of hand-foot syndrome when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 83]
Granisetron	N.A.	Nephrotoxicity	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes GG + GT.		[ 31]
Palonosetron	N.A.	Nephrotoxicity	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes GG + GT.		[ 31]
Cyclophosphamide	N.A.	Drug-induced Liver Injury	Genotype TT is associated with increased likelihood of drug-induced liver injury when treated with cyclophosphamide, docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 117]
Docetaxel	N.A.	Drug-induced Liver Injury	Genotype TT is associated with increased likelihood of drug-induced liver injury when treated with cyclophosphamide, docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 117]
Epirubicin	N.A.	Drug-induced Liver Injury	Genotype TT is associated with increased likelihood of drug-induced liver injury when treated with cyclophosphamide, docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 117]
Rosuvastatin	N.A.	Drug Toxicity	Genotype TT is associated with increased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype GG.		[ 69]
Dolutegravir	N.A.	Neutropenia	Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes GG + GT.		[ 90]
Imatinib	N.A.	Progression-free Survival	Genotype TT is associated with increased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes GG + GT.		[ 118]
Sunitinib	N.A.	Neutropenia	Genotype TT is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 108]
Apixaban	N.A.	Neutropenia	Genotype TT is associated with increased concentrations of apixaban in people with Atrial Fibrillation as compared to genotype GG.		[ 92]
Felodipine	N.A.	Neutropenia	Genotype TT is associated with increased exposure to felodipine in healthy individuals as compared to genotypes GG + GT.		[ 119]
Sunitinib	N.A.	Neutropenia	Genotype TT is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 108]
Opioid Anesthetics	N.A.	Neutropenia	Genotype TT is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes GG + GT.		[ 95]
Other General Anesthetics	N.A.	Neutropenia	Genotype TT is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes GG + GT.		[ 95]
Volatile Anesthetics	N.A.	Neutropenia	Genotype TT is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes GG + GT.		[ 95]
Rivaroxaban	N.A.	Discontinuation	Genotype TT is associated with increased half-life time of rivaroxaban in healthy individuals as compared to genotypes GG + GT.		[ 121]
Lamotrigine	N.A.	Exanthema	Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes GG + GT.		[ 27]
Sunitinib	N.A.	Drug Toxicity	Genotype TT is associated with increased exposure to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 122]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is associated with decreased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 88]
N-desethyl Sunitinib	N.A.	Overall Survival	Genotype TT is associated with increased concentrations of n-desethyl sunitinib and sunitinib in women with Carcinoma, Renal Cell.		[ 123]
Sunitinib	N.A.	Overall Survival	Genotype TT is associated with increased concentrations of n-desethyl sunitinib and sunitinib in women with Carcinoma, Renal Cell.		[ 123]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.		[ 80]
Capecitabine	N.A.	Colorectal Neoplasms	Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.		[ 29]
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.		[ 29]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.		[ 29]
Oxaliplatin	N.A.	Colorectal Neoplasms	Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.		[ 29]
Sulfasalazine	N.A.	Rheumatoid Arthritis	Patients with the TT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.		[ 57]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.		[ 81]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the TT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype based on the finding of the GT genotype being associated with decreased metabolism as compared to the GG genotype. Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 82]
Sunitinib	N.A.	Neoplasms	Genotype TT is associated with increased risk of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 83]
Sunitinib	N.A.	Neoplasms	Genotype TT is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.		[ 108]
Lamotrigine	N.A.	Epilepsy	Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes GG + GT.		[ 27]
Lamotrigine	N.A.	Epilepsy	Patients with the rs2231142 TT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.		[ 64]
Atorvastatin	N.A.	Epilepsy	Patients with the rs2231142 TT genotype may have an increased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.		[ 86]
Rosuvastatin	N.A.	Epilepsy	The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 TT genotype may have increased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.		[ 87]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype TT is associated with decreased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 88]
Gefitinib	N.A.	Lung Neoplasms	No patients with the TT genotype were available for analysis, but patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism, including patients with the GG genotype, and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.		[ 89]
Gemcitabine	N.A.	Non-small Cell Lung Carcinoma	Patients with the TT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.		[ 33]
Dolutegravir	N.A.	HIV Infectious Disease	Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes GG + GT.		[ 90]
Sulfasalazine	N.A.	Beta-thalassemia And Related Diseases	Patients with the TT genotype may have decreased clearance and metabolism of sulfasalazine as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.		[ 91]
Apixaban	N.A.	Atrial Fibrillation	Genotype TT is associated with increased concentrations of apixaban in people with Atrial Fibrillation as compared to genotype GG.		[ 92]
Cyclophosphamide	N.A.	Breast Neoplasms	No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 93]
Doxorubicin	N.A.	Breast Neoplasms	No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 93]
Fluorouracil	N.A.	Breast Neoplasms	No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 93]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 115]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 115]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 115]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 115]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 94]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 94]
Methotrexate	N.A.	Lymphoma, T-cell	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 94]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 94]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 96]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 96]
Methotrexate	N.A.	Drug Toxicity	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 96]
Methotrexate	N.A.	Lymphoma, T-cell	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 96]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.		[ 96]
Rosuvastatin	N.A.	Statin-related Myopathy	The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 TT genotype may have a higher risk of statin-related myopathy when treated with rosuvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.		[ 87]
Rosuvastatin	N.A.	Hypercholesterolemia	Patients with the rs2231142 TT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 44]
Rosuvastatin	N.A.	Myocardial Infarction	Patients with the rs2231142 TT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 44]
Allopurinol	N.A.	Gout	Patients with the rs2231142 TT genotype may require an increased dose of allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol dose requirements.		[ 40]
Allopurinol	N.A.	Gout	Patients with the rs2231142 TT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.		[ 51]
Opioids	N.A.	Neoplasm	Correlated with the increased drug response (compare with genotypes GG + Gt)		[ 95]
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Apixaban	Drug Info	Atrial Fibrillation	Correlated with the increased drug clearance in patients (compare with Genotype TT)		[ 114]
Atorvastatin	N.A.	Mucositis	Genotypes GG + GT are not associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 115]
Apixaban	N.A.	Discontinuation	Genotypes GG + GT is associated with increased clearance of apixaban in people with Atrial Fibrillation as compared to genotype TT.		[ 114]
Apixaban	N.A.	Atrial Fibrillation	Genotypes GG + GT is associated with increased clearance of apixaban in people with Atrial Fibrillation as compared to genotype TT.		[ 114]
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:         66 Drugs in Total
Allopurinol	Drug Info	Gout	Correlated with the decreased drug response in patients (compare with genotype GG)		[ 116]
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 117]
Tenofovir	Drug Info	HIV Infection	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 80]
Sunitinib	Drug Info	Neoplasm	Correlated with the increased drug exposure in patients (compare with genotype GG)		[ 119]
Sulfasalazine	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with genotype GG)		[ 57]
Gemcitabine	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased progression-free survival in patients (compare with genotype GG); Correlated with the increased severity of thrombocytopenia in patients (compare with genotype GG); Irrelevant to the overall survival in patients (compare with genotype GG)		[ 33]
Efavirenz	Drug Info	HIV Infection	Correlated with the increased abnormal dreams risk in patients (compare with genotype GG)		[ 81]
Rosuvastatin	N.A.	Elevated Liver Enzymes	Genotypes GT + TT is associated with increased likelihood of Elevated liver enzymes when treated with rosuvastatin in people with Acute coronary syndrome, Dyslipidaemia, Diabetes Mellitus or Cardiovascular Disease as compared to genotype GG.		[ 123]
Rosuvastatin	N.A.	Elevated Liver Enzymes	Genotypes GT + TT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype GG.		[ 124]
Rivaroxaban	N.A.	Elevated Liver Enzymes	Genotypes GT + TT is associated with increased exposure to rivaroxaban in healthy individuals as compared to genotype GG.		[ 97]
Clozapine	N.A.	Adverse Events	Genotypes GT + TT is associated with increased dose-adjusted trough concentrations of clozapine in people with Schizophrenia as compared to genotype GG.		[ 126]
Imatinib	N.A.	Neutropenia	Genotypes GT + TT is associated with increased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.		[ 127]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes GT + TT are not associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype GG.		[ 86]
Simvastatin	N.A.	Statin-related Myopathy	Genotypes GT + TT are not associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype GG.		[ 86]
Lamotrigine	N.A.	Drug-induced Liver Injury	Genotypes GT + TT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.		[ 117]
Risperidone	N.A.	Adverse Events	Genotypes GT + TT is associated with increased risk of adverse events when treated with risperidone in children as compared to genotype GG.		[ 129]
Rosuvastatin	N.A.	Adverse Events	Genotypes GT + TT is associated with increased concentrations of rosuvastatin as compared to genotype GG.		[ 130]
N-desmethyltamoxifen	N.A.	Drug Toxicity	Genotypes GT + TT is associated with increased concentrations of n-desmethyltamoxifen in women with Breast Neoplasms as compared to genotype GG.		[ 131]
Atorvastatin	N.A.	Discontinuation	Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.		[ 132]
Fluvastatin	N.A.	Discontinuation	Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.		[ 132]
Rosuvastatin	N.A.	Discontinuation	Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.		[ 132]
Atorvastatin	N.A.	Anemia	Genotypes GT + TT are not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype GG.		[ 133]
Rosuvastatin	N.A.	Mucositis	Genotypes GT + TT are not associated with response to rosuvastatin as compared to genotype GG.		[ 134]
Rosuvastatin	N.A.	Mucositis	Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.		[ 87]
Iguratimod	N.A.	Mucositis	Genotypes GT + TT is associated with increased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 136]
Risperidone	N.A.	Drug Toxicity	Genotypes GT + TT is associated with decreased dose-adjusted trough concentrations of risperidone in children as compared to genotype GG.		[ 129]
Fluvastatin	N.A.	Adverse Events	Genotypes GT + TT are associated with increased likelihood of adverse events when treated with fluvastatin in people with Kidney Transplantation as compared to genotype GG.		[ 137]
Rosuvastatin	N.A.	Neutropenia	Genotypes GT + TT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.		[ 138]
Atorvastatin	N.A.	Drug Toxicity	Genotypes GT + TT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis or Toxic liver disease when treated with atorvastatin as compared to genotype GG.		[ 139]
Atorvastatin	N.A.	Muscular Diseases	Genotypes GT + TT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis or Toxic liver disease when treated with atorvastatin as compared to genotype GG.		[ 139]
Atorvastatin	N.A.	Rhabdomyolysis	Genotypes GT + TT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis or Toxic liver disease when treated with atorvastatin as compared to genotype GG.		[ 139]
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes GT + TT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis or Toxic liver disease when treated with atorvastatin as compared to genotype GG.		[ 139]
Irinotecan	N.A.	Drug Toxicity	Genotypes GT + TT is associated with increased likelihood of Drug Toxicity when treated with irinotecan in people with Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms or Stomach Neoplasms as compared to genotype GG.		[ 140]
Gefitinib	N.A.	Drug Toxicity	Genotypes GT + TT is not associated with increased likelihood of Drug Toxicity, Diarrhea, Pneumonia or Toxic liver disease when treated with gefitinib in people with Non-Small Cell Lung Carcinoma as compared to genotype GG.		[ 55]
Gefitinib	N.A.	Diarrhea	Genotypes GT + TT is not associated with increased likelihood of Drug Toxicity, Diarrhea, Pneumonia or Toxic liver disease when treated with gefitinib in people with Non-Small Cell Lung Carcinoma as compared to genotype GG.		[ 55]
Gefitinib	N.A.	Pneumonia	Genotypes GT + TT is not associated with increased likelihood of Drug Toxicity, Diarrhea, Pneumonia or Toxic liver disease when treated with gefitinib in people with Non-Small Cell Lung Carcinoma as compared to genotype GG.		[ 55]
Gefitinib	N.A.	Toxic Liver Disease	Genotypes GT + TT is not associated with increased likelihood of Drug Toxicity, Diarrhea, Pneumonia or Toxic liver disease when treated with gefitinib in people with Non-Small Cell Lung Carcinoma as compared to genotype GG.		[ 55]
Sulfasalazine	N.A.	Toxic Liver Disease	Genotypes GT + TT are associated with increased response to sulfasalazine in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 57]
Sunitinib	N.A.	Death	Genotypes GT + TT is associated with increased exposure to sunitinib in people with Neoplasms as compared to genotype GG.		[ 119]
Allopurinol	N.A.	Progression-free Survival	Genotypes GT + TT are associated with decreased response to allopurinol in people with Gout as compared to genotype GG.		[ 116]
Pazopanib	N.A.	Toxic Liver Disease	Genotypes GT + TT is associated with increased likelihood of Toxic liver disease when treated with pazopanib and simvastatin in people with Neoplasms as compared to genotype GG.		[ 142]
Simvastatin	N.A.	Toxic Liver Disease	Genotypes GT + TT is associated with increased likelihood of Toxic liver disease when treated with pazopanib and simvastatin in people with Neoplasms as compared to genotype GG.		[ 142]
Gemcitabine	N.A.	Thrombocytopenia	Genotypes GT + TT are associated with increased severity of Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.		[ 33]
Gemcitabine	N.A.	Overall Survival	Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.		[ 33]
Gemcitabine	N.A.	Progression-free Survival	Genotypes GT + TT are associated with increased progression-free survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.		[ 33]
Rosuvastatin	N.A.	Muscular Diseases	Genotypes GT + TT are not associated with risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype GG.		[ 87]
Tenofovir	N.A.	Discontinuation	Genotypes GT + TT are associated with increased concentrations of tenofovir in women with HIV Infections as compared to genotype GG.		[ 80]
Diazepam	N.A.	Discontinuation	Genotypes GT + TT is associated with increased concentrations of diazepam in healthy individuals as compared to genotype GG (assigned as normal metabolizer phenotype) .		[ 143]
Pazopanib	N.A.	Discontinuation	Genotypes GT + TT is not associated with decreased clearance of pazopanib in people with Neoplasms as compared to genotype GG.		[ 24]
Methotrexate	N.A.	Drug Toxicity	Genotypes GT + TT are not associated with risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 107]
Eltrombopag	N.A.	Drug Toxicity	Genotypes GT + TT is associated with increased clearance of eltrombopag in children with Anemia, Aplastic as compared to genotype GG.		[ 146]
Efavirenz	N.A.	Drug Toxicity	Genotypes GT + TT are associated with increased risk of abnormal dreams when treated with efavirenz in people with HIV Infections as compared to genotype GG.		[ 81]
Voriconazole	N.A.	Overall Survival	Genotypes GT + TT is associated with increased dose-adjusted trough concentrations of voriconazole in people with Leukemia, Lymphoma or Myelodysplastic Syndromes as compared to genotype GG.		[ 147]
Tenofovir	N.A.	HIV Infectious Disease	Genotypes GT + TT are associated with increased concentrations of tenofovir in women with HIV Infections as compared to genotype GG.		[ 80]
Sulfasalazine	N.A.	Rheumatoid Arthritis	Genotypes GT + TT are associated with increased response to sulfasalazine in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 57]
Efavirenz	N.A.	HIV Infectious Disease	Genotypes GT + TT are associated with increased risk of abnormal dreams when treated with efavirenz in people with HIV Infections as compared to genotype GG.		[ 81]
Lamotrigine	N.A.	Epilepsy	Genotypes GT + TT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.		[ 117]
Atorvastatin	N.A.	Epilepsy	Genotypes GT + TT are not associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype GG.		[ 86]
Atorvastatin	N.A.	Epilepsy	Genotypes GT + TT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis or Toxic liver disease when treated with atorvastatin as compared to genotype GG.		[ 139]
Gemcitabine	N.A.	Non-small Cell Lung Carcinoma	Genotypes GT + TT are associated with increased progression-free survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.		[ 33]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes GT + TT are not associated with risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 107]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes GT + TT are not associated with risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 107]
Methotrexate	N.A.	Lymphoma, T-cell	Genotypes GT + TT are not associated with risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 107]
Methotrexate	N.A.	Osteosarcoma	Genotypes GT + TT are not associated with risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 107]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotypes GT + TT are not associated with risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype GG.		[ 87]
Allopurinol	N.A.	Gout	Genotypes GT + TT are associated with decreased response to allopurinol in people with Gout as compared to genotype GG.		[ 116]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Methotrexate	N.A.	Mucositis	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 94]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 94]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 94]
Methotrexate	N.A.	Lymphoma, T-cell	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 94]
Methotrexate	N.A.	Osteosarcoma	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 94]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Drug Toxicity	Genotype CT is associated with increased response to rosuvastatin in healthy individuals as compared to genotype CC.		[ 138]
Genetic Polymorphism	rs41282401
Site of GPD	chr4:88115014 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G
Minor Allele Frequency	G=0.0002/1 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele G)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele G)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele G)		[ 1]
Dasatinib	N.A.	Neutropenia	Allele C is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele G.		[ 1]
Imatinib	N.A.	Neutropenia	Allele C is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele G.		[ 1]
Nilotinib	N.A.	Neutropenia	Allele C is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele G.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CG genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CG genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CG genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Nilotinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.		[ 1]
Genetic Polymorphism	rs45605536
Site of GPD	chr4:88097518 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0018/9 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Dasatinib	N.A.	Neutropenia	Allele T is associated with increased sensitivity to dasatinib or imatinib in K562 cells as compared to allele C.		[ 1]
Imatinib	N.A.	Neutropenia	Allele T is associated with increased sensitivity to dasatinib or imatinib in K562 cells as compared to allele C.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Genetic Polymorphism	rs58818712
Site of GPD	chr4:88097526 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Allele C	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele A)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele A)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele A)		[ 1]
Dasatinib	N.A.	Adverse Events	Allele C is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele A.		[ 1]
Imatinib	N.A.	Adverse Events	Allele C is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele A.		[ 1]
Nilotinib	N.A.	Adverse Events	Allele C is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele A.		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Dasatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.		[ 1]
Genetic Polymorphism	rs7699188
Site of GPD	chr4:88174909 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	A=0.2460/1232 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased grade 3-4 nonhematological toxicity risk in patients (compare with allele G); Correlated with the increased tumor response rate in patients (compare with allele G)		[ 139]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased grade 3-4 nonhematological toxicity risk in patients (compare with allele G); Correlated with the increased tumor response rate in patients (compare with allele G)		[ 139]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased grade 3-4 nonhematological toxicity risk in patients (compare with allele G); Correlated with the increased tumor response rate in patients (compare with allele G)		[ 139]
Fluorouracil	N.A.	Nephrotoxicity	Allele A is associated with increased tumor response rate when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.		[ 139]
Irinotecan	N.A.	Nephrotoxicity	Allele A is associated with increased tumor response rate when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.		[ 139]
Leucovorin	N.A.	Nephrotoxicity	Allele A is associated with increased tumor response rate when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.		[ 139]
Fluorouracil	N.A.	Colorectal Neoplasms	Allele A is associated with increased tumor response rate when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.		[ 139]
Irinotecan	N.A.	Colorectal Neoplasms	Allele A is associated with increased tumor response rate when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.		[ 139]
Leucovorin	N.A.	Colorectal Neoplasms	Allele A is associated with increased tumor response rate when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.		[ 139]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the AG genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype or may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AG genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype or may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the AG genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype or may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.		[ 139]
Genetic Polymorphism	rs12505410
Site of GPD	chr4:88109689 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	G=0.2794/1399 (Global)
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased drug response in patients (compare with Genotype TT)		[ 6]
Imatinib	N.A.	Drug Toxicity	Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.		[ 6]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.		[ 6]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Drug Toxicity	Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.		[ 6]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	N.A.	Neutropenia	Genotype GG is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes GT + TT.		[ 5]
Methotrexate	N.A.	Osteosarcoma	Genotype GG is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes GT + TT.		[ 5]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the GG genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.		[ 5]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the GT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.		[ 5]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Genetic Polymorphism	rs17731538
Site of GPD	chr4:88134227 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.0960/481 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Psoriasis	Correlated with the increased drug response in patients (compare with allele AG)		[ 2]
Methotrexate	N.A.	Anemia	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.		[ 2]
Methotrexate	N.A.	Psoriasis	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.		[ 2]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.		[ 5]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Discontinuation	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 15]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Psoriasis	Patients with the AA genotype were not studied. However, patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Psoriasis	Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 2]
Genetic Polymorphism	rs2199939
Site of GPD	chr8:40053975 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0946/474 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response (compare with genotype CC)		[ 140]
Genetic Polymorphism	rs2725252
Site of GPD	chr4:88140758 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	A=0.4145/2076 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased drug response in patients (compare with genotype AA)		[ 6]
Imatinib	N.A.	Drug Toxicity	Genotypes AC + CC is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype AA.		[ 6]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotypes AC + CC is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype AA.		[ 6]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Neutropenia	Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.		[ 6]
Methotrexate	N.A.	Neutropenia	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 5]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AA genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.		[ 6]
Genetic Polymorphism	rs3114020
Site of GPD	chr4:88162514 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.4249/2128 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with Genotype TT)		[ 117]
Lamotrigine	N.A.	Drug-induced Liver Injury	Genotypes CC + CT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.		[ 117]
Lamotrigine	N.A.	Epilepsy	Genotypes CC + CT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.		[ 117]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Carboplatin	N.A.	Death	Genotypes CT + TT is associated with increased risk of Death when treated with carboplatin, etoposide and ifosfamide in children with Central Nervous System Neoplasms as compared to genotype CC.		[ 141]
Etoposide	N.A.	Death	Genotypes CT + TT is associated with increased risk of Death when treated with carboplatin, etoposide and ifosfamide in children with Central Nervous System Neoplasms as compared to genotype CC.		[ 141]
Ifosfamide	N.A.	Death	Genotypes CT + TT is associated with increased risk of Death when treated with carboplatin, etoposide and ifosfamide in children with Central Nervous System Neoplasms as compared to genotype CC.		[ 141]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Discontinuation	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.		[ 15]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Lamotrigine	N.A.	Thromboembolism	Allele C is not associated with dose of lamotrigine in people with Epilepsy as compared to allele T.		[ 64]
Lamotrigine	N.A.	Epilepsy	Allele C is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.		[ 64]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lamotrigine	N.A.	Epilepsy	Patients with the rs3114020 CC genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.		[ 64]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lamotrigine	N.A.	Epilepsy	Patients with the rs3114020 CT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.		[ 64]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lamotrigine	N.A.	Epilepsy	Patients with the rs3114020 TT genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the CC and CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.		[ 64]
Genetic Polymorphism	rs4148157
Site of GPD	chr4:88099782 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.1006/504 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Topotecan	Drug Info	Brain Neoplasm	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 142]
Topotecan	N.A.	Neutropenia	Genotypes AA + AG is associated with increased concentrations of topotecan in children with Brain Neoplasms as compared to genotype GG.		[ 142]
Topotecan	N.A.	Brain Neoplasms	Genotypes AA + AG is associated with increased concentrations of topotecan in children with Brain Neoplasms as compared to genotype GG.		[ 142]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Allopurinol	N.A.	Toxic Liver Disease	Allele A is associated with decreased response to allopurinol as compared to allele G.		[ 58]
Antiepileptics	N.A.	Discontinuation	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 15]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Topotecan	N.A.	Brain Neoplasms	Infants and children with the AA genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.		[ 142]
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		[ 58]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Topotecan	N.A.	Brain Neoplasms	Infants and children with the AG genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.		[ 142]
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		[ 58]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Topotecan	N.A.	Brain Neoplasms	Infants and children with the GG genotype and brain tumors may have decreased absorption and lower concentrations of topotecan compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affect pharmacokinetics of topotecan.		[ 142]
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		[ 58]
Genetic Polymorphism	rs3219191
Site of GPD	chr4:88159568 (GRCh38.p12)
GPD Type	Indel
Allele(s) in dbSNP	GTGAGTG / GTGAGTGAGTG / GTGAGTGAGTGAGTG
Minor Allele Frequency	GTGAGTG=0.5860/1159 (Global)
Genotype del	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Neutropenia	Allele del is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele TGAG.		[ 15]
Genetic Polymorphism	rs2622604
Site of GPD	chr4:88157772 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.1690/334 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Osimertinib	N.A.	Diarrhea	Genotype TT is associated with increased likelihood of Diarrhea when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.		[ 143]
Gefitinib	N.A.	Adverse Events	Genotype TT is not associated with overall survival when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.		[ 72]
Gefitinib	N.A.	Drug Toxicity	Genotype TT is not associated with increased Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.		[ 72]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Erlotinib	N.A.	Drug Toxicity	Genotype CC is associated with decreased mean AUC of erlotinib as compared to genotypes CT + TT.		[ 144]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 5]
Irinotecan	N.A.	Drug Toxicity	Allele T is associated with increased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C.		[ 146]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gefitinib	N.A.	Exanthema	Genotype CT is associated with increased severity of Exanthema when treated with gefitinib in women with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 103]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Apixaban	N.A.	Hemorrhage	Genotypes CT + TT is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.		[ 146]
Rivaroxaban	N.A.	Hemorrhage	Genotypes CT + TT is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.		[ 146]
Gefitinib	N.A.	Drug Toxicity	Genotypes CT + TT is associated with increased time to response to gefitinib in healthy individuals as compared to genotype CC.		[ 147]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sunitinib	N.A.	Drug Toxicity	Allele C is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele T.		[ 16]
Genetic Polymorphism	rs2231164
Site of GPD	chr4:88094705 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.4330/856 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antineoplastic Agents	N.A.	Neutropenia	Genotypes CC + CT are associated with increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to genotype TT.		[ 148]
Genetic Polymorphism	rs1448784
Site of GPD	chr4:88091168 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.9320/1844 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Platinum Compounds	N.A.	Progression-free Survival	Genotype GG is associated with decreased progression-free survival when treated with Platinum compounds in people with Lung Neoplasms as compared to genotypes AA + AG.		[ 149]
Genetic Polymorphism	rs2622628
Site of GPD	chr4:88108100 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.2410/476 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lamotrigine	N.A.	Drug-induced Liver Injury	Genotype AA is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype CC.		[ 117]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Discontinuation	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 15]
Genetic Polymorphism	rs2199936
Site of GPD	chr4:88124179 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.1450/286 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Adverse Events	Genotypes AA + AG are associated with increased response to rosuvastatin as compared to genotype GG.		[ 140]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Colorectal Neoplasms	Patients with the rs2199936 AA genotype may have increased response (decreased LDL-C reduction) to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to rosuvastatin.		[ 140]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Colorectal Neoplasms	Patients with the rs2199936 AG genotype may have increased response (decreased LDL-C reduction) to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to rosuvastatin.		[ 140]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Colorectal Neoplasms	Patients with the rs2199936 GG genotype may have decreased response (decreased LDL-C reduction) to rosuvastatin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence the response to rosuvastatin.		[ 140]
Genetic Polymorphism	rs10011796
Site of GPD	chr4:88169725 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.4370/864 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Allopurinol	N.A.	Drug Toxicity	Allele T is not associated with decreased response to allopurinol in people with Gout as compared to allele C.		[ 51]
Allopurinol	N.A.	Hypercholesterolemia	Allele T is not associated with dose of allopurinol in people with Gout as compared to allele C.		[ 40]
Allopurinol	N.A.	Death	Allele T is associated with decreased response to allopurinol as compared to allele C.		[ 58]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Progression-free Survival	Genotypes CT + TT are not associated with response to allopurinol in people with Gout as compared to genotype CC.		[ 116]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.		[ 116]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.		[ 116]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.		[ 116]
Genetic Polymorphism	rs2622629
Site of GPD	chr4:88172912 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.7080/1401 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Atorvastatin	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotypes CC + CT.		[ 150]
Fluvastatin	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotypes CC + CT.		[ 150]
Lovastatin	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotypes CC + CT.		[ 150]
Pitavastatin	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotypes CC + CT.		[ 150]
Simvastatin	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotypes CC + CT.		[ 150]
Genetic Polymorphism	rs1481012
Site of GPD	chr4:88117930 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.8860/1753 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Mucositis	Genotypes AG + GG are associated with increased response to rosuvastatin as compared to genotype AA.		[ 140]
Genetic Polymorphism	rs72552713
Site of GPD	chr4:88131805 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9990/1977 (Global)
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sulfasalazine	N.A.	Drug Toxicity	Genotype AG is associated with decreased metabolism of sulfasalazine in healthy individuals.		[ 104]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Gefitinib	N.A.	Drug Toxicity	Allele A is not associated with increased risk of Drug Toxicity when treated with gefitinib as compared to allele G.		[ 46]
Pazopanib	N.A.	Overall Survival	Allele A is associated with overall survival when treated with pazopanib in people with Carcinoma, Renal Cell.		[ 152]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sulfasalazine	N.A.	Osteosarcoma	Patients with the GG genotype may have increased clearance of sulfasalazine as compared to patients with the AG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).		[ 104]
Genetic Polymorphism	rs2725264
Site of GPD	chr4:88104957 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.3760/744 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Neutropenia	Genotypes CT + TT are not associated with severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype CC.		[ 152]
Genetic Polymorphism	rs4148155
Site of GPD	chr4:88133515 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.8870/1755 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Toxic Liver Disease	Allele G is associated with decreased response to allopurinol as compared to allele A.		[ 58]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Beta-thalassemia And Related Diseases	Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		[ 58]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Beta-thalassemia And Related Diseases	Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		[ 58]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Beta-thalassemia And Related Diseases	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		[ 58]
Genetic Polymorphism	rs45499402
Site of GPD	chr4:88122482 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.8860/1753 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Toxic Liver Disease	Allele C is associated with decreased response to allopurinol.		[ 58]
Genetic Polymorphism	rs76979899
Site of GPD	chr4:88104089 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9030/1787 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Death	Allele T is associated with decreased response to allopurinol as compared to allele C.		[ 58]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		[ 58]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		[ 58]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Allopurinol	N.A.	Non-small Cell Lung Carcinoma	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		[ 58]
Genetic Polymorphism	rs6857600
Site of GPD	chr4:88144923 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.6890/1363 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 5]
Genetic Polymorphism	rs2622621
Site of GPD	chr4:88109768 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G
Minor Allele Frequency	C=0.6740/1333 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 5]
Genetic Polymorphism	rs13137622
Site of GPD	chr4:88141361 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	G=0.7260/1436 (Global)
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Neutropenia	Genotypes GT + TT are associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 5]
Methotrexate	N.A.	Osteosarcoma	Genotypes GT + TT are associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 5]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.		[ 5]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the GT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.		[ 5]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.		[ 5]
Genetic Polymorphism	rs3114018
Site of GPD	chr4:88143429 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G / A>T
Minor Allele Frequency	A=0.5100/1009 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 5]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Oxaliplatin	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with severity of Peripheral Nervous System Diseases when treated with oxaliplatin in people with Colonic Neoplasms as compared to allele C.		[ 153]
Genotypes AA + AC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Apixaban	N.A.	Hemorrhage	Genotypes AA + AC is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.		[ 146]
Rivaroxaban	N.A.	Hemorrhage	Genotypes AA + AC is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.		[ 146]
Genetic Polymorphism	rs1564481
Site of GPD	chr4:88140113 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.7050/1395 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 5]
Genetic Polymorphism	rs2725256
Site of GPD	chr4:88129846 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.6640/1314 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Discontinuation	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 15]
Genetic Polymorphism	rs2231148
Site of GPD	chr4:88107326 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.7840/1551 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Discontinuation	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 15]
Genetic Polymorphism	rs17731799
Site of GPD	chr4:88147303 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.5560/1100 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Discontinuation	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 15]
Genetic Polymorphism	rs3109823
Site of GPD	chr4:88143450 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.3410/674 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Discontinuation	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 15]
References
1	Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenet Genomics. 2014 Jan;24(1):52-61.
2	Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008 Aug;128(8):1925-9.
3	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics. 2018 Jul 01;19(11):913-925.
4	Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics. 2016 Apr;17(6):561-72.
5	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018 Dec;58(12):1541-1549.
6	High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget. 2013 Oct;4(10):1582-91.
7	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. J Clin Pharmacol. 2018 Dec;58(12):1550-1556.
8	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur J Clin Pharmacol. 2016 Sep;72(9):1155-7.
9	ABCC1, ABCG2 and FOXP3: Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis. Biomedicines. 2023 Sep 19;11(9).
10	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
11	Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. Pharmacogenomics J. 2015 Oct;15(5):385-90.
12	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007 Aug;17(8):647-56.
13	Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer. Br J Clin Pharmacol. 2025 Feb;91(2):297-305.
14	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics J. 2019 Oct;19(5):473-479.
15	Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 2011 Mar;12(3):319-25.
16	Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2015 Aug;13(4):350-358.
17	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20.
18	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacol Res. 2016 Sep;111:501-508.
19	Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine. 2023 May;59:101955.
20	Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017 Jun 6;8(23):37761-37772.
21	Potential association of. Pharmacogenomics. 2024;25(8-9):367-375.
22	Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2011 Feb 01;17(3):620-9.
23	Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Cancer Chemother Pharmacol. 2017 Apr;79(4):759-766.
24	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. Clin Pharmacokinet. 2019 May;58(5):651-658.
25	Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One. 2014 Jan 3;9(1):e82681.
26	Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome Med. 2016 Nov 08;8(1):119.
27	Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res. 2016 Nov;127:186-190.
28	Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
29	Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol. 2014 Jan;31(1):802.
30	ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. Oncotarget. 2017 Aug 29;8(35):58292-58303.
31	Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. Support Care Cancer. 2018 May;26(5):1505-1513.
32	Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol. 2018 Sep;84(9):2106-2119.
33	Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC Cancer. 2018 May 11;18(1):555.
34	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics. 2016 Apr;17(6):583-91.
35	Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. Int J Hematol. 2013 Dec;98(6):702-7.
36	Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone Marrow Transplant. 2011 Jan;46(1):90-7.
37	Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events. Front Genet. 2022;13:982955.
38	Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide. Pharmacogenomics. 2021 Dec;22(18):1201-1209.
39	Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015 May;97(5):518-25.
40	The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. Br J Clin Pharmacol. 2018 May;84(5):937-943.
41	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013 Aug;6(4):400-8.
42	Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet Genomics. 2010 Oct;20(10):634-7.
43	Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet. 2010 Jun;3(3):276-85.
44	ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
45	Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015 Mar;71(3):329-40.
46	Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 2010 Sep;66(4):691-8.
47	Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia. Int Immunopharmacol. 2024 May 30;133:112090.
48	Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors. Drug Metab Pharmacokinet. 2022 Apr;43:100441.
49	Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma. Oncotarget. 2018 Mar 30;9(24):17160-17170.
50	Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. Drug Metab Pharmacokinet. 2013;28(3):196-202.
51	Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology (Oxford). 2018 Apr 01;57(4):656-660.
52	Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies. J Clin Pharmacol. 2019 Sep;59(9):1236-1243.
53	Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study. J Clin Pharm Ther. 2021 Dec;46(6):1557-1563.
54	Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. Eur J Clin Pharmacol. 2017 Jun;73(6):717-726.
55	Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With. Anticancer Res. 2024 Dec;44(12):5361-5370.
56	Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
57	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics J. 2014 Aug;14(4):350-5.
58	Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. Clin Pharmacol Ther. 2019 Sep;106(3):623-631.
59	Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction. PLoS One. 2016;11(2):e0148177.
60	Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):297-304.
61	Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics. 2017 Jan;18(1):35-56.
62	SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2007 Nov;82(5):541-7.
63	Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget. 2017 Feb 07;8(6):9388-9398.
64	Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics J. 2020 Dec;20(6):845-856.
65	Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci. 2020 Jun;23(6):800-809.
66	High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?. J Cancer Res Clin Oncol. 2014 Aug;140(8):1359-65.
67	Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther. 2004 Jul;76(1):38-44.
68	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10;28(20):3227-33.
69	Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013 Aug;14(11):1283-94.
70	Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta. 2006 Nov;373(1-2):99-103.
71	Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 Jul;16(4):274-81.
72	Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. 2011 Feb;12(2):159-70.
73	Genetic Variants in the. Genes (Basel). 2024 May 07;15(5).
74	Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic Study. J Infect Dis. 2025 Feb 26.
75	Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer. Int J Mol Sci. 2023 Mar 13;24(6).
76	Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients. Anticancer Res. 2023 Apr;43(4):1775-1783.
77	Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer. 2016 Mar;93:69-76.
78	Genetic polymorphisms are associated with individual susceptibility to dexmedetomidine. Front Genet. 2023;14:1187415.
79	Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol. 2014 May;70(5):539-47.
80	Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV. Pharmacogenomics J. 2018 Apr;18(2):245-250.
81	Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics. 2013 Jul;14(10):1167-78.
82	Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008 Nov 1;14(21):7102-9.
83	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013 Oct;72(4):825-35.
84	ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009 Aug;86(2):197-203.
85	Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009 Oct;10(10):1617-24.
86	Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. Clin Pharmacol Ther. 2018 Jul;104(1):178-187.
87	Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharmacol Sin. 2019 Apr;40(4):492-499.
88	Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics. 2010 Jun;20(6):367-76.
89	Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
90	High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genomics. 2017 Nov;27(11):416-419.
91	Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
92	Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017 Sep;27(9):329-336.
93	Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018 Jan 10;9(10):9114-9136.
94	Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Oct;57(4):612-9.
95	Clinical and pharmacogenetics associated with recovery time from general anesthesia. Pharmacogenomics. 2018 Sep 1;19(14):1111-1123.
96	Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012 Apr 01;118(7):1856-67.
97	Effects of ABCG2 421C>A genetic polymorphism on the pharmacokinetics of rivaroxaban in healthy Chinese subjects. Xenobiotica. 2025 Jun 25:1-17.
98	Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease. Arch Med Sci Atheroscler Dis. 2017;2:e68-e75.
99	Pharmacokinetics of intravenous paracetamol in elderly patients. Clin Pharmacokinet. 2011 Feb;50(2):121-9.
100	Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics. Eur J Clin Pharmacol. 2013 Aug;69(8):1611-3.
101	Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther. 2012 Jul 12;14(4):R163.
102	Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2024 Dec 23;95(1):12.
103	Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile. Pharmaceuticals (Basel). 2024 Aug 07;17(8).
104	Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene. Br J Clin Pharmacol. 2015 Nov;80(5):1236-7.
105	Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther. 2008 Jul;84(1):95-103.
106	Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS One. 2015 Aug 5;10(8):e0134102.
107	Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014 Aug;15(11):1479-94.
108	Clinical and genetic risk factors for the prediction of hepatotoxicity induced by a docetaxel, epirubicin and cyclophosphamideregimen in breast cancer patients. Pharmacogenomics. 2021 Jan;22(2):87-98.
109	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2015 Jan;75(1):173-82.
110	The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther. 2017 Jun;42(3):345-349.
111	ABCG2 polymorphism and rivaroxaban pharmacokinetics in healthy individuals after a single dose. Braz J Med Biol Res. 2024;57:e13257.
112	ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol. 2010 Jun;21(6):1382-1383.
113	Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. BMC Cancer. 2014 Dec 16;14:964.
114	Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018 Jun;84(6):1301-1312.
115	Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Drug Metab Pharmacokinet. 2019 Dec;34(6):387-395.
116	ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2017 Mar;17(2):201-203.
117	Polymorphisms of ABCG2, ABCB1 and HNF4 are associated with Lamotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet. 2015 Aug;30(4):282-7.
118	Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs. 2015 Feb;33(1):257-68.
119	Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population. Hum Genomics. 2025 Apr 25;19(1):44.
120	Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. Eur J Clin Pharmacol. 2020 Jul;76(7):939-946.
121	Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Ann Clin Biochem. 2017 Nov;54(6):677-685.
122	Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor. Pharmacogenomics. 2023 May;24(7):425-434.
123	The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J. 2018 May 22;18(3):422-430.
124	The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022 Feb 24;14(3).
125	Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Pharmacogenet Genomics. 2023 Jan 01;33(1):10-18.
126	Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants. Pharmacogenet Genomics. 2023 Sep 01;33(7):153-160.
127	Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. J Clin Pharm Ther. 2018 Feb;43(1):87-91.
128	Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Sci Rep. 2019 Dec 19;9(1):19410.
129	Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis. Pharmacogenomics. 2018 Apr;19(5):383-392.
130	CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. Pharmacogenomics. 2013 Sep;14(12):1419-31.
131	Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol. 2015 Mar;71(3):341-55.
132	ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics. 2015 Jul;16(8):803-15.
133	Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clin Pharmacokinet. 2023 Nov;62(11):1589-1597.
134	Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 2012 Sep;23(9):2470-2471.
135	Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam. Biomed Pharmacother. 2022 Nov;155:113747.
136	Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia. J Clin Pharmacol. 2024 Aug;64(8):932-943.
137	Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing. Pharmacogenomics J. 2023 Nov;23(6):201-209.
138	The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein. Basic Clin Pharmacol Toxicol. 2017 Sep;121(3):195-201.
139	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics. 2013 Oct;23(10):549-57.
140	Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012 Apr 1;5(2):257-64.
141	Factors Influencing Mortality in Children with Central Nervous System Tumors: A Cohort Study on Clinical Characteristics and Genetic Markers. Genes (Basel). 2024 Apr 09;15(4).
142	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metab Dispos. 2016 Jul;44(7):1116-22.
143	CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients. Front Pharmacol. 2023;14:1222435.
144	Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01;26(7):1119-27.
145	Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet. 2009 Oct;54(10):572-80.
146	ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban. Drug Des Devel Ther. 2023;17:2513-2522.
147	Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers. Xenobiotica. 2024 Jan;54(1):38-44.
148	Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas. 2011 Jul;40(5):657-63.
149	The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients. Pharmgenomics Pers Med. 2022;15:817-825.
150	Transporter Genes and statin-induced Hepatotoxicity. Cardiovasc Drugs Ther. 2024 May 29.
151	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br J Cancer. 2015 Mar 31;112(7):1190-8.
152	ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 Jan;18(1):35-42.
153	Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Ann Oncol. 2016 Jun;27(6):1143-1148.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.